Medicine – Goodpasture Syndrome

Goodpasture syndrome is an autoimmune pulmonary–renal syndrome caused by antibodies directed against the glomerular basement membrane (GBM). The same antibodies can also attack basement membranes in the pulmonary alveolar capillaries, producing the classic combination of:

Rapidly progressive glomerulonephritis + pulmonary haemorrhage.

The more precise modern term for the renal disease is:

Anti-GBM disease.

When anti-GBM disease causes both renal and pulmonary involvement, the term Goodpasture syndrome is commonly used.

1. Autoantibody Against the GBM

The disease is caused by:

Anti-glomerular basement membrane antibodies.

These antibodies are directed mainly against the:

α3 chain of type IV collagen

within basement membranes.

The most important target is the:

NC1 domain of the α3 chain of type IV collagen.

2. Sites of Antibody Attack

The antibodies bind to basement membranes in:

Renal glomerular capillaries.

and

Pulmonary alveolar capillaries.

This explains why the two major organs involved are:

Kidneys

and

Lungs.

3. Pulmonary–Renal Syndrome

Goodpasture syndrome is one of the classical causes of:

Pulmonary–renal syndrome.

This means the simultaneous presence of:

Pulmonary haemorrhage

and

Glomerulonephritis.

Other important causes of pulmonary–renal syndrome include:

ANCA-associated vasculitis, especially granulomatosis with polyangiitis and microscopic polyangiitis.

4. Renal Pathology

The renal lesion is typically:

Rapidly progressive glomerulonephritis, or RPGN.

This causes a rapid decline in renal function over:

Days to weeks.

5. Crescentic Glomerulonephritis

On renal biopsy, anti-GBM disease typically produces:

Crescentic glomerulonephritis.

Crescents form in Bowman’s space as a result of severe glomerular capillary injury.

These crescents are composed of:

Proliferating parietal epithelial cells

and

Inflammatory cells.

6. Why Crescents Matter

Crescent formation indicates:

Severe glomerular injury.

The greater the proportion of glomeruli containing crescents, the worse the renal prognosis tends to be.

7. Immunofluorescence

The classic renal biopsy finding is:

Linear deposition of IgG along the GBM.

Complement, particularly:

C3,

may also be deposited.

This is a very high-yield pathological finding.

8. Linear versus Granular Immunofluorescence

Remember:

Anti-GBM disease → linear IgG deposition.

By contrast:

Immune-complex glomerulonephritis → granular deposition.

This distinction is extremely useful in exams.

9. Pulmonary Haemorrhage

Anti-GBM antibodies can also damage the pulmonary alveolar basement membrane.

This causes:

Diffuse alveolar haemorrhage.

The patient may develop:

Haemoptysis.

Breathlessness.

Hypoxaemia.

Anaemia.

10. Haemoptysis

One of the classic presenting symptoms is:

Haemoptysis.

This may range from:

Blood-streaked sputum

to

Massive pulmonary haemorrhage.

However, absence of visible haemoptysis does not completely exclude alveolar haemorrhage.

11. Breathlessness

Pulmonary haemorrhage may cause:

Acute dyspnoea.

This results from:

Blood filling the alveoli.

Impaired gas exchange.

Hypoxaemia.

Severe cases may progress to:

Respiratory failure.

12. Anaemia

Repeated or severe pulmonary haemorrhage can produce:

Iron-deficiency or acute blood-loss anaemia.

Therefore, a falling haemoglobin level may be an important clue.

13. Haematuria

Renal involvement commonly causes:

Microscopic haematuria

or sometimes:

Visible haematuria.

Urinalysis often shows features of glomerular bleeding.

14. Dysmorphic Red Cells

Because bleeding originates from the glomeruli, urine microscopy may demonstrate:

Dysmorphic red blood cells.

These support:

Glomerular haematuria.

15. Red Blood Cell Casts

A particularly important urinary finding is:

Red blood cell casts.

These strongly suggest:

Glomerulonephritis.

Therefore:

Haematuria + RBC casts + rapidly rising creatinine → think rapidly progressive GN.

16. Proteinuria

Proteinuria may occur, usually:

Mild to moderate.

It is not usually the dominant feature compared with haematuria and rapidly declining renal function.

17. Progressive Renal Failure

Renal function can deteriorate very rapidly.

Patients may develop:

Acute kidney injury.

In severe cases this can progress rapidly to:

Dialysis-dependent kidney failure.

Older notes may call this:

Progressive renal failure.

The modern terminology is more appropriately:

Rapidly progressive AKI due to crescentic glomerulonephritis.

18. Clinical Pattern

The classic presentation is:

Haemoptysis + haematuria + rapidly rising creatinine.

This combination should immediately raise concern for:

Pulmonary–renal syndrome.

19. Age and Epidemiology

Anti-GBM disease is rare.

It can occur at different ages, but classical teaching recognises peaks in:

Younger adults

and

Older adults.

Pulmonary haemorrhage is more commonly seen in younger patients.

20. Environmental Triggers

Pulmonary haemorrhage may be promoted by factors that damage the alveolar basement membrane.

Important associations include:

Cigarette smoking.

Hydrocarbon exposure.

Respiratory infection.

Smoking is particularly important because it can increase pulmonary involvement.

21. Diagnosis – Anti-GBM Antibodies

A key diagnostic test is:

Serum anti-GBM antibody testing.

A positive result in the appropriate clinical setting strongly supports the diagnosis.

22. Renal Biopsy

Renal biopsy is important when feasible because it can:

Confirm the diagnosis.

Assess the severity of glomerular injury.

Estimate renal prognosis.

The key features are:

Crescentic GN

and

Linear IgG staining along the GBM.

23. Chest Imaging

Chest X-ray or CT may demonstrate:

Bilateral diffuse alveolar infiltrates

due to pulmonary haemorrhage.

These changes can resemble:

Pulmonary oedema.

Pneumonia.

Therefore, the clinical context is essential.

24. Bronchoscopy

In selected cases, bronchoscopy with bronchoalveolar lavage can help confirm:

Diffuse alveolar haemorrhage.

Sequential lavage samples may become increasingly blood-stained.

25. ANCA Testing

Some patients with anti-GBM disease also have:

ANCA antibodies.

These are called:

Double-positive patients.

This overlap is clinically important because the disease may behave partly like:

ANCA-associated vasculitis.

26. Double-Positive Disease

Patients positive for both:

Anti-GBM antibodies

and

ANCA

may have a greater tendency to relapse than classic isolated anti-GBM disease.

Therefore, their long-term management may require closer follow-up.

27. Treatment Is an Emergency

Goodpasture syndrome is a:

Medical emergency.

Treatment should begin rapidly because ongoing antibody-mediated injury can cause irreversible:

Kidney failure

and

Life-threatening pulmonary haemorrhage.

28. Three Main Components of Treatment

The traditional and still important treatment combination is:

Plasma exchange.

Corticosteroids.

Cyclophosphamide.

Each has a different role.

29. Plasma Exchange

Plasma exchange, or plasmapheresis, removes circulating:

Anti-GBM antibodies

from the blood.

It is usually performed repeatedly until antibody levels become undetectable or sufficiently suppressed.

30. Why Plasma Exchange Is Important

Plasma exchange reduces the amount of antibody available to attack:

Glomerular

and

Alveolar basement membranes.

It is particularly important when there is:

Pulmonary haemorrhage

or

Potentially recoverable renal disease.

31. Corticosteroids

High-dose:

Corticosteroids

are used to suppress the inflammatory response.

Treatment often begins with:

High-dose intravenous or oral glucocorticoids

depending on severity and local protocol.

32. Cyclophosphamide

Cyclophosphamide suppresses the immune cells producing the pathogenic antibodies.

Its role is to:

Stop further anti-GBM antibody production.

Therefore:

Plasma exchange removes existing antibody

while

Cyclophosphamide reduces new antibody production.

33. How the Three Treatments Work Together

Remember the mechanism:

Plasma exchange → removes anti-GBM antibody.

Cyclophosphamide → stops new antibody production.

Steroids → suppress inflammatory tissue injury.

This is the classic therapeutic strategy.

34. Supportive Management

Patients may also require:

Oxygen therapy.

Blood transfusion for severe anaemia.

Mechanical ventilation for respiratory failure.

Treatment of electrolyte abnormalities.

Fluid management.

Dialysis if severe AKI develops.

35. Dialysis

Dialysis may be required for:

Severe hyperkalaemia.

Metabolic acidosis.

Fluid overload.

Uraemic complications.

Severe renal failure.

However, the requirement for dialysis at presentation has major prognostic implications.

36. Prognosis

The original statement is correct:

Prognosis depends strongly on renal function at presentation.

Patients who begin treatment before severe irreversible glomerular destruction have a much better chance of renal recovery.

37. Poor Renal Prognostic Features

Poor renal recovery is more likely when the patient presents with:

Very high serum creatinine.

Oliguria or anuria.

Dialysis dependence.

A very high percentage of crescents on biopsy.

Extensive glomerular scarring.

38. Importance of Dialysis Dependence at Presentation

If a patient is already:

Dialysis dependent

with extensive crescent formation and irreversible glomerular destruction, recovery of kidney function may be unlikely.

However, treatment may still be urgently required if there is:

Active pulmonary haemorrhage.

39. Pulmonary Prognosis

Pulmonary haemorrhage can be dramatic and life-threatening, but it is often:

More reversible than the renal damage

if treated promptly.

This is because glomerular scarring can become permanent, whereas alveolar haemorrhage may resolve after antibody suppression.

40. Relapse

Classic isolated anti-GBM disease is generally:

Monophasic.

Relapse is uncommon once anti-GBM antibodies disappear.

This differs from:

ANCA-associated vasculitis,

which has a greater tendency to relapse.

41. Kidney Transplantation

Patients who progress to ESKD may eventually undergo:

Kidney transplantation.

Transplantation is generally delayed until:

Anti-GBM antibodies have remained undetectable for an appropriate period.

This reduces the risk of recurrent disease in the transplanted kidney.

42. Goodpasture Syndrome – Note Form

Autoantibody:

Anti-GBM antibody.

Target:

α3 chain of type IV collagen.

Organs affected:

Kidneys.

Lungs.

Renal lesion:

Rapidly progressive crescentic glomerulonephritis.

Pulmonary lesion:

Diffuse alveolar haemorrhage.

Clinical features:

Haemoptysis.

Breathlessness.

Pulmonary haemorrhage.

Haematuria.

Rapidly rising creatinine.

AKI.

Possible dialysis dependence.

Urine:

Dysmorphic RBCs.

RBC casts.

Proteinuria may occur.

Serology:

Anti-GBM antibodies.

Check ANCA because double-positive disease can occur.

Renal biopsy:

Crescentic glomerulonephritis.

Immunofluorescence:

Linear IgG deposition along GBM.

Treatment:

Plasma exchange.

High-dose corticosteroids.

Cyclophosphamide.

Supportive care.

Dialysis if required.

43. Goodpasture versus ANCA Vasculitis – Note Form

Goodpasture / anti-GBM disease:

Anti-GBM antibodies.

Linear IgG on immunofluorescence.

Pulmonary haemorrhage + RPGN.

Relapse usually uncommon.

ANCA-associated vasculitis:

ANCA may be positive.

Usually pauci-immune glomerulonephritis.

Often associated with systemic vasculitic features.

Relapse is more common.

44. Important Corrections to the Original Notes

The original note states:

“Autoantibody to GBM.”

This is correct but can be made more precise:

Anti-GBM antibodies target the α3 chain of type IV collagen.

The renal lesion:

Rapidly progressive GN

is more specifically:

CRESCENTIC GLOMERULONEPHRITIS.

The characteristic biopsy immunofluorescence finding should be added:

LINEAR IgG DEPOSITION ALONG THE GBM.

The older description:

“Progressive renal failure”

is better understood as:

Rapidly progressive AKI due to crescentic glomerulonephritis, potentially progressing to ESKD.

Key Clinical Pattern

Remember:

GOODPASTURE = LUNG + KIDNEY.

The classic presentation is:

HAEMOPTYSIS + HAEMATURIA + RAPIDLY RISING CREATININE.

Pathology:

ANTI-GBM ANTIBODY → CRESCENTIC RPGN + PULMONARY ALVEOLAR HAEMORRHAGE.

Biopsy:

LINEAR IgG ALONG THE GBM.

Treatment:

PLASMA EXCHANGE + STEROIDS + CYCLOPHOSPHAMIDE.

And prognosis:

THE WORSE THE RENAL FUNCTION AT PRESENTATION, ESPECIALLY IF ALREADY DIALYSIS-DEPENDENT WITH EXTENSIVE CRESCENTS, THE LOWER THE CHANCE OF RENAL RECOVERY.